Merck and Artiva have agreed to partner on an initial two CAR-NK programs, with the pharma giant retaining an option for a third. Merck has already selected the first target, and the companies have a short list of preferred targets for the other programs, Peter Flynn, PhD, Artiva’s Chief Operating Officer, told GEN . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge